Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective
Canadian Journal of Physiology and Pharmacology · 01.12.2025 · 103 (12) · 369-377
DOI: 10.1139/cjpp-2025-0148 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Canadian Journal of Physiology and Pharmacology, erschienen am 01.12.2025. Verfasst von Inmaculada Ros-Madrid und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain. Hauptthemen laut MEDLINE: Glucagon-Like Peptide-1 Receptor Agonists, Anti-Inflammatory Agents, Inflammation. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: Instituto de Salud Carlos III.
Abstract (Originalsprache)
Incretin-based therapies, particularly glucagon-like peptide-1 receptor agonists (GLP-1RAs), exert a wide range of beneficial effects beyond glycemic control, largely mediated by their anti-inflammatory properties. Chronic low-grade inflammation is a common pathological mechanism underlying metabolic, cardiovascular, hepatic, and neurodegenerative diseases. GLP-1RAs reduce systemic and tissue-specific inflammation through both direct and indirect mechanisms, including inhibition of nuclear factor kappa B signaling, reduction of proinflammatory cytokines, and modulation of immune cell activity, such as that of macrophages and microglia. In type 2 diabetes and obesity, GLP-1RAs improve insulin sensitivity and endothelial function by attenuating inflammation. In metabolic dysfunction-associated steatotic liver disease, GLP-1RAs reduce hepatic steatosis and fibrosis by modulating inflammation in hepatocytes and Kupffer cells. In cardiovascular disease, they mitigate atherosclerosis progression and improve vascular health. GLP-1RAs also exert direct nephroprotective effects by reducing renal inflammation, oxidative stress, and glomerular hyperfiltration in both diabetic and nondiabetic models. GLP-RAs have been also associated with the preservation of cognitive and motor function. Preclinical studies suggest that these neuroprotective effects may involve the attenuation of neuroinflammation and reduced aggregation of pathological proteins. Overall, these pleiotropic actions position incretin-based therapies as promising tools for the management of complex chronic diseases with an inflammatory component.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Endocrinology and Nutrition, Virgen de la Arrixaca University Hospital, 30120 Murcia, Spain.
- Obesity, Diabetes and Metabolism Research Group, Biomedical Research Institute of Murcia (IMIB), 30120 Murcia, Spain.
ORCID-Profile: Inmaculada Ros-Madrid
Förderung
- Instituto de Salud Carlos III
Zitieren
APA
Ros-Madrid, I., Cano-Mármol, R., Ferrer-Gomez, M., & Ramos-Molina, B. (2025). Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Canadian Journal of Physiology and Pharmacology, 103(12), 369-377. https://doi.org/10.1139/cjpp-2025-0148
Vancouver
Ros-Madrid I, Cano-Mármol R, Ferrer-Gomez M, Ramos-Molina B. Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective. Canadian Journal of Physiology and Pharmacology. 2025;103(12):369-377. doi:10.1139/cjpp-2025-0148
BibTeX
@article{RosMadrid2025,
author = {Ros-Madrid, Inmaculada and Cano-Mármol, Rosario Paloma and Ferrer-Gomez, Mercedes and Ramos-Molina, Bruno},
title = {Anti-inflammatory properties of GLP-1 receptor agonists and other ancillary benefits from a pharmacological perspective},
journal = {Canadian Journal of Physiology and Pharmacology},
year = {2025},
volume = {103},
number = {12},
pages = {369--377},
doi = {10.1139/cjpp-2025-0148}
}
EUVIMED